Pérez-Topete SE, Miranda-Aquino T, Muñoz-Ramírez MR, Barrientos-Quintanilla LA, Calderón JA, Herrera E

Language: Spanish
References: 9
Page: 256-259
PDF size: 694.86 Kb.

ABSTRACT

This paper reports the case of a 53-year-old female patients with breast cancer; doxorubicin chemotherapy was administered seven days before admission; patient began with abdominal pain and fecaloid vomit, thus she was taken to the emergency room in shock. She was admitted to the intensive care unit with a diagnosis of septic shock secondary to neutropenic colitis. Antibiotics, hydration and vasopressors were given. Transthoracic echocardiography was made with LVEF of 28%, cardiotoxicity due to anthracyclines was diagnosed, so levosimendan was started, improving LVEF 40%; patient presented good clinical evolution and was discharged.

REFERENCES

1. Von Hoff DD, Layard MW, Basa P, Davis HL, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.

2. Mertens AC, Yasui Y, Neglia JP, Potter JD, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 2001;19:3163-3172.

3. Alexander J, Dainiak N, Berger HJ, Goldman L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-283.

4. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985;55:2761-2765.

5. Cardinale D, Sandri MT, Colombo A, Colombo N, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-2754.

6. Lipshultz SE, Miller TM, Scully RE, Lipstiz SR, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012;30:1042-1049.

7. Garcia JAP, Simvoulidis LF, Salluh JI, Hansen MH, et al. Levosimendan in acute decompensation of anthracyclineinduced cardiotoxicity. Int J Cardiol 2007;118:406-407.

8. Cadinale D, Colombo A, Lamantia G, Colombo N, et al. Anthracycline Induced cardiomyophathy. J Am Coll Cardiol 2010;55:213-220.

9. Silber JH, Cnaan A, Clark BJ, Paridon SM, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820-828.